Alkermes plc

The stock has a good momentum. Alkermes plc has good value characteristics. Alkermes plc is a mediocre stock to choose.

Alkermes Plc IS a biopharmaceutical company, which engages in the development, research, and commerc...

News

Los Angeles Capital Management LLC Decreases Stake in Alkermes plc (NASDAQ:ALKS)

Ticker Report Los Angeles Capital Management LLC lessened its holdings in Alkermes plc (NASDAQ:ALKS - Free Report) by 6.2% during the second quarter, according to its most recent 13F filing with the Securities...\n more…

Los Angeles Capital Management LLC Cuts Position in Alkermes plc (NASDAQ:ALKS)

Zolmax Los Angeles Capital Management LLC lessened its position in Alkermes plc (NASDAQ:ALKS - Free Report) by 6.2% during the second quarter, according to the company in its most recent Form 13F filing...\n more…

Oregon Public Employees Retirement Fund Sells 3,800 Shares of Alkermes plc (NASDAQ:ALKS)

Zolmax Oregon Public Employees Retirement Fund reduced its holdings in shares of Alkermes plc (NASDAQ:ALKS - Free Report) by 8.5% in the 2nd quarter, according to its most recent filing with the Securities...\n more…

Alkermes plc (NASDAQ:ALKS) Shares Sold by CIBC Asset Management Inc

Ticker Report CIBC Asset Management Inc trimmed its stake in shares of Alkermes plc (NASDAQ:ALKS - Free Report) by 4.2% during the 2nd quarter, according to the company in its most recent Form 13F filing with the...\n more…

Q1 2025 EPS Estimates for Alkermes plc Reduced by Analyst (NASDAQ:ALKS)

Zolmax Alkermes plc (NASDAQ:ALKS - Free Report) - Research analysts at Zacks Research dropped their Q1 2025 EPS estimates for Alkermes in a research report issued on Thursday, September 5th. Zacks...\n more…

Q1 2025 Earnings Forecast for Alkermes plc Issued By Zacks Research (NASDAQ:ALKS)

Ticker Report Alkermes plc (NASDAQ:ALKS - Free Report) - Research analysts at Zacks Research reduced their Q1 2025 earnings per share estimates for Alkermes in a report released on Thursday, September 5th. Zacks...\n more…